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Altered Platelet Function in Patients with Severe Congestive 
Heart Failure* 
Syed M. Jafri, MD,+ Jeanne M. Riddle, PhD,* Sundara B.K. Raman, MD,^  
and Sidney Goldstein, MD'I 
Platelet function was assessed in 15 patients with severe congestive heart failure (CHF) and in 26 
control subjects of similar ages. The platelet count (mm'), surface reactivity, aggregometry studies, 
release factors, and circulating aggregates were investigated. The mean number of circulating 
platelets was normal, but a hyperactive platelet response was found in 53% ofthe CHF patients. CHF 
patients had a 42% mean for the spread type platelet, and the average number of aggregates was 64: 
control subjects had a 12% mean for the spread type platelet, and the average number of aggregates 
was 40 (p < 0.05). Aggregation with all ofthe inducers was normal, aUhough 27% of CHF patients 
showed spontaneous aggregation. The mean plasma levels of both platelet factor 4 and beta-
thromboglobulin were abnormally elevated. No circulating platelet aggregates were detected. Our 
studies indicate that platelet function is abnormal in patients with CHF. The abnormal platelet 
reactivity found might contribute to the increased incidence of thromboembolic events ob.'ierved in 
CHF patients. (Henry Ford Hosp Med J 1986:34:156-9) 
Thromboembolism is an important cause of morbidity and mortality in patients with congestive heart failure (I). The 
pathophysiologic mechanisms responsible for these events are 
not clearly delineated. An increased incidence of thromboem-
bolic episodes was observed in patients with larger cardio-
thoracic ratios and in those with chronic atrial fibrillation (2). 
Because of the established association between congestive heart 
failure and thromboembolism as well as the accepted role of 
blood platelets in the formation of a thrombus (3), we studied the 
platelet response of 15 patients with severe congestive heart 
failure. Their results were compared to data obtained for con-
trols of similar ages. 
Scant information is available regarding platelet function in 
patients with heart failure (4). The objective of our study was to 
determine i f platelet function was normal or abnormal in a group 
of patients with severe congestive heart failure. 
Materials and Methods 
Patient information 
Fifteen patients, 11 men and four women, with chronic con-
gestive heart failure (New York Heart Association funcdonal 
class I I I to IV) whose mean age was 61 years (range 42 to 78 
years) were included in the study. The etiology for heart failure 
was coronary artery disease in ten patients and cardiomyopathy 
in the other five patients. Two patients had a history of throm-
boembolic events, one of whom showed atrial fibrillation. Pa-
tients selected for this study did not have hypertension, a recent 
acute myocardial infarction, a recent cerebrovascular accident, 
unstable angina, primary valvular disease, or significant hepatic 
or renal dysfunction. 
Six study patients received either a single antiplatelet agent or 
two platelet-active agents. The antithrombotic agents used were 
aspirin (1), heparin subcutaneously (3), andibuprofen (2). Blood 
samples obtained from the heart failure patients were drawn 
through an indwelling arterial catheter 
Control groups 
Two groups of control subjects were used to establish our nor-
mal values. Data for evaluation of surface reactivity and ag-
gregation using electron microscopy, platelet release factors in-
cluding platelet factor 4 and beta-thromboglobulin, platelet 
count/mm\ as well as the platelet aggregate ratio were obtained 
from 26 asymptomatic subjects who came to a general medical 
clinic for a routine physical examination. This group's mean age 
was 60 years (range 42 to 77 years), which was not significantly 
different from the mean age of our heart failure patients. These 
control subjects, 19 men and seven women, did not have any dis-
ease processes that produced recognizable clinical symptoms, 
and none were on any dmgs known to alter platelet function. 
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Normal values for the platelet aggregation studies were es-
tablished from data collected on 50 asymptomatic subjects of 
various ages. For the controls, peripheral blood was drawn by a 
venipuncture using a siliconized butterfly infusion set and a 21-
gauge needle. 
Platelet count 
The number of circulating platelets (platelet count/mm') was 
determined by using platelet-rich plasma obtained from whole 
blood anticoagulated with ethylenediamine tetraaceric acid 
(EDTA) processed in a Thrombo-fuge (Coulter Electronics, Inc, 
Hialeah, FL). The platelet-rich plasma was diluted with Isoton II 
and evaluated with a Coulter Counter, Model ZBl. 
Platelet electron microscopic survey 
Our standardized in vitro method (5) provided a morphologic 
assessment of three separate phases of the platelet response: 
adhesion, surface activation, and aggregadon. The platelets' 
morphologic states were evaluated at the magnification and reso-
lution capability ofthe transmission electron microscope. Three 
distinct types of platelets were observed: round, dendritic, and 
spread types. A platelet differential count included the percent 
of round, dendritic, and spread types of platelets found on exam-
ination of 100 single platelets. The numberof platelet aggregates 
seen during evaluation of these platelets was also determined. 
Based on the limits of our control data (± two standard devia-
tions), a hyperactive platelet response was defined as greater 
than 36% of the spread type platelet and/or more than 94 aggre-
gates/100 single platelets counted. 
Platelet aggregometry 
Aggregometry studies were performed with a Bio-Data Ag-
gregadon Profiler (PAP-4, Biodata Corp, Philadelphia, PA) 
using platelet-rich plasma (250 X lO** platelets/L) in combina-
tion with the following stimulants: epinephrine, adenosine di-
phosphate (ADP), collagen, and arachidonic acid. Specimens 
that showed an aggregation rate of over 70% were tested for 
spontaneous aggregation and were also studied using different 
concentrations of the inducers. 
Platelet aggregate ratio 
The presence or absence of circulating platelet aggregates was 
established according to the method of Wu and Hoak (6). 
Platelet release factors 
Plasma levels of the platelet release factors (platelet factor 4 
and beta-thromboglobulin) were measured by radioimmuno-
assay methods (7). 
Statistical analysis 
The unpaired Student's t-test and chi-square test were used to 
determine the level of significance for various tests of platelet 




A comparison of the control subjects and the patients with 
congestive heart failure showed that the number of circulating 
platelets was within the normal range (126,000 to 450,000/mm') 
at 257,000/mm\ 
Electron microscope differential count 
Transmission electron microscopy demonstrated a stads-
tically significant (p < 0.05) decrease in the number of the 
dendritic type platelet and a concomitant increase in the percent 
of the spread type platelet in differential counts of patients with 
congestive heart failure. The mean number of dendritic platelets 
was 74% for the control group and 49% for the congestive heart 
failure patients. In contrast, a mean value of only 12% of the 
spread type platelet was found in the differential counts of the 
control subjects, whereas the congestive heart failure patients 
showed 42% of the spread type platelet (Figure) (p < 0.05). 
A significantly increased mean number (p < 0.05) of platelet 
aggregates (64 aggregates) was also noted for patients with con-
gestive heart failure compared to the control subjects (40 aggre-
gates). A hyperactive platelet response was found in three of 26 
control subjects (12%) and in eight of 15 (53%) of the congestive 
heart failure patients (p < 0.05). Therefore, the surface reac-
tivity and/or aggregation of over half of the patients with con-
gestive heart failure were abnormally increased. 
Platelet aggregate ratio 
The mean platelet aggregate ratio of 0,74 found in our control 
subjects was not significantly different from the average rado 
found for the patients with congestive heart failure (Table 1). 
Platelet aggregometry 
Evaluation of platelet aggregation induced by the various 
stimulants for the entire group of patients with congestive heart 
failure did not show any significant changes (Table 2). However, 
platelets from four of the 15 padents (27%) aggregated spon-
taneously. In contrast, platelets removed from five other patients 
showed a release-type defect with two or more inducers. All of 
these padents had received drugs known to inhibit platelet ac-
tivity, primarily aspirin and ibuprofen. 
Platelet release factors 
The mean levels of both platelet factor 4 and beta-throm-
boglobulin were uniformly increased (p < 0.05) (Table 2). Nine 
patients (60%) had an increased level of platelet factor 4, and 13 
patients (87%) had an abnormal plasma concentration of beta-
thromboglobulin. 
Subgroup analysis 
Subgroups of patients with conditions known to alter platelet 
function, such as gout and diabetes mellitus, and patients who 
received antiplatelet agents were analyzed separately. Data col-
lected from patients with coronary artery disease were com-
pared to results obtained from patients with cardiomyopathy. 
Results of all the platelet function tests were not significantly 
different in the subgroups compared to patients with congestive 
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Table 1 
Tests of Platelet Function 
Platelet count ( X IOOO) 
Electron microscope differential count 
Round type (%) 
Dendritic type (%) 
Spread type (%) 
Platelet aggregates (n) 
Platelet aggregate ratio 
Controls CHF 
288 ± 162 257 ± 184 
14 + 28 9 ± 18 
74 ± 36 49* ± 58 
12 ± 24 42* ± 64 
40 ± 54 64* ± 126 
0.74 ± 0.38 0.87 ± 0.54 
*p < 0.05 between control subjects and CHF patients. 
CHF = congestive heart failure. 
Table 2 
Platelet Aggregation and Release Factors 
Controls CHF 
Aggregometry 
ADP (%) 5i) 8 57 ± 30 
Epinephrine (%) 50 X 51 ± 4S 
Collagen (%) 50 8 52 44 
Arachidonic acid (%) 50 8 52 ± 36 
Release factors 
Platelet factor (ng/mL) 7.51 -+- 5.72 21.06* 22.48 
Beta-thromboglobulin (ng/mL) 42.93 ± .34.64 126.97* + 83.22 
*p < 0.05 between control subjects and CHF patients. 
CHF = congestive heart failure. 
heart failure who did not have a platelet-modifying state. The 
platelet abnormalities were independent of whether the underly-
ing etiology for the congestive heart failure was coronary artery 
disease or cardiomyopathy (Table 3). 
Discussion 
Clinically recognized thromboembolism in patients with con-
gestive heart failure reportedly occurs at a frequency of 15% to 
20% (1,2). Evidence of either arterial or pulmonary emboli was 
found in 22% of patients with dilated cardiomyopathy at autopsy 
and in 18% by clinical examination of the survivors. Enlarged 
cardiac size and atrial fibrillation conelated with a higher inci-
dence of thromboembolic episodes (2). 
Limited information is cunentiy available regarding platelet 
function in patients with congestive heart failure (4). Our inves-
tigation included tests that measured both the early stage (adhe-
sion and surface activation) and later stage (aggregation and 
release of platelet-specific proteins) of the platelet response. 
Abnormalities of platelet function shown in our study were not 
reported previously in these patients. Using electron micros-
copy, we found hyperactive platelets expressed as an abnor-
mally increased number of the spread type platelet which is 
an early feature of platelet activation. The cohesive capacity of 
the platelets, demonstrated by their ability to form aggregates, 
was also evaluated in the procedure which utilized the transmis-
sion electron microscope. The average number of aggregates 
counted during the classification of 100 single platelets was sig-
Figure—A spread type platelet (arrow) and two platelet aggregates seen during a differential count on a patient with 
congestive heart failure (X5,600). 
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nificantly increased in the differential counts of the patients with 
congestive heart failure. Advantages of our platelet electron mi-
croscopic survey over routine platelet aggregometry include 
direct evaluation of the early stages of platelet activation and 
assessment of the overall aggregability of a platelet population. 
During the procedure the platelets are maintained in a compati-
ble environment of anticoagulated whole blood and are not sub-
jected to extensive manipulation such as the shear forces of 
centrifugation. 
Routine aggregometry which incorporates a centrifugation 
step, however, also showed abnormalities of the platelet function 
in blood samples removed from these patients. In 27% of the 
congestive heart failure patients (four of 15 patients), the pre-
pared platelet-rich plasma aggregated spontaneously without an 
additional in vitro chemical inducer. The remaining patients 
showed either a normal amount of aggregation (seven of 15 pa-
tients) or diminished aggregation, which was probably related to 
recent ingestion of agents known to inhibit platelet function 
(four of 15 padents). 
Plasma levels of platelet release factors, platelet factor 4 and 
beta-thromboglobulin, measures of in vivo platelet activation, 
were also abnormally increased (8,9). 
We did not find circulating platelet aggregates in the blood of 
these patients. Our results conflict with an earlier study in which 
platelet aggregates were demonstrated in the circulation of some 
patients with congestive heart failure (4), We suspect that this 
discrepancy may be explained by differences in the group of 
control subjects used to establish the normal values in the two 
investigations. Our control group consisted of healthy subjects 
of similar ages, while the previous study used young volunteers 
(mean age of 32 years). The mean value for our platelet aggre-
gate rado was 0.74 rather than 0.91 which was reported in the 
other study (4). The lower ratio thus changed the interpretation 
of whether circulating aggregates were present. 
Our findings show evidence of altered platelet function in pa-
tients with severe congestive heart failure. While the exact 
mechanisms responsible for these abnormalities require fur-
ther clarification, changes secondary to hemodynamic and neu-
rohormonal alterations could be important. Activation of the 
circulating platelets might occur in relation to the following he-
modynamic alterations: 1) stasis due to a low cardiac output 
state, or turbulence from valvular insufficiency because of di-
lated cardiac chambers; or 2) release of vasoactive substances 
because of increased peripheral vascular resistance, Leyels of 
norepinephrine (10), renin-angiotensin (11), and prostaglandin 
12 and E2 (12) are frequendy increased in heart failure patients. 
Elevated catecholamine levels previously have been associated 
with platelet activation and hyperaggregation in a variety of con-
ditions such as acute myocardial infarction (13) and mitral valve 
prolapse (14), 
Our study demonstrates that the platelet response is fre-
quently abnormal in patients with congestive heart failure. The 
altered platelet function is independent of associated platelet-
modifying diseases and is consistent whether the etiology of the 
congestive heart failure is coronary artery disease or cardio-
myopathy. The increased platelet reactivity may directly 
contribute to the high incidence of thromboembolism seen 
clinically in these patients. 
Table 3 
Subgroup Analysis of CHF Patients 
ETIOLOGY OF CHF ANTI-PLATELET DRUGS 
CAD CM Yes No 
Platelet count ( X 1000) 247 277 238 279 
Surface activation 
% Spread type 52 20 51 31 
Total aggregates 65 61 72 54 
Aggregometry 
ADP 59 52 48 ill 
Epinephrine 54 45 37 67 
Collagen 58 ^0 39 66 
Arachidonic acid 56 45 44 !:.! 
Release faclors 
Platelet factor 4 21.22 20.74 20.15 22.10 
Beta-thromboglobulin 129.66 121.60 135.65 117.06 
Platelet aggregate ratio 0.83 0.96 0.79 0.97 
No. of patients 10 5 6 9 
CAD = coronary artery disease. 
CM — cardiomyopathy. 
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